FY2022 Earnings Forecast for Graphite Bio, Inc. (NASDAQ:GRPH) Issued By SVB Leerink

Graphite Bio, Inc. (NASDAQ:GRPHGet Rating) – Equities research analysts at SVB Leerink raised their FY2022 earnings per share (EPS) estimates for Graphite Bio in a report issued on Wednesday, November 9th. SVB Leerink analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.82) for the year, up from their previous forecast of ($1.83). SVB Leerink currently has a “Outperform” rating on the stock. The consensus estimate for Graphite Bio’s current full-year earnings is ($1.76) per share. SVB Leerink also issued estimates for Graphite Bio’s Q4 2022 earnings at ($0.40) EPS and FY2023 earnings at ($2.76) EPS.

Separately, Cantor Fitzgerald began coverage on Graphite Bio in a research note on Thursday, September 15th. They issued an “overweight” rating and a $12.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.83.

Graphite Bio Stock Up 0.3 %

NASDAQ GRPH opened at $3.41 on Monday. The firm has a market cap of $198.30 million, a PE ratio of -1.94 and a beta of 0.36. The company has a 50 day moving average price of $3.32 and a 200 day moving average price of $3.17. Graphite Bio has a 52 week low of $2.07 and a 52 week high of $13.39.

Graphite Bio (NASDAQ:GRPHGet Rating) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.01.

Institutional Investors Weigh In On Graphite Bio

Hedge funds have recently modified their holdings of the business. Strs Ohio lifted its holdings in Graphite Bio by 89.2% in the first quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $35,000 after buying an additional 3,300 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Graphite Bio in the 3rd quarter valued at about $34,000. Walleye Capital LLC bought a new stake in Graphite Bio in the 1st quarter valued at approximately $57,000. ExodusPoint Capital Management LP bought a new stake in shares of Graphite Bio in the third quarter worth $41,000. Finally, American International Group Inc. boosted its stake in shares of Graphite Bio by 69.7% during the 1st quarter. American International Group Inc. now owns 14,656 shares of the company’s stock worth $75,000 after buying an additional 6,020 shares during the last quarter. 51.83% of the stock is owned by institutional investors.

About Graphite Bio

(Get Rating)

Graphite Bio, Inc, a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.

Featured Stories

Earnings History and Estimates for Graphite Bio (NASDAQ:GRPH)

Receive News & Ratings for Graphite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graphite Bio and related companies with MarketBeat.com's FREE daily email newsletter.